An analysis of the phase 3 GEMZ trial presented at CNS 2026 showed that fenfluramine produced comparable seizure reductions and safety outcomes in children and adults with CDKL5 deficiency disorder.
|Slideshows|June 14, 2017
New Insights About Accelerated Long-Term Forgetting in Epilepsy
Author(s)Veronica Hackethal, MD
Here’s evidence that ALF may be an important memory disorder in subgroups of patients with epilepsy.
Advertisement
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
At a NeurologyLive Clinical Forum in Philadelphia, Jessica D. Schulte, MD, PhD, of NYU Grossman School of Medicine, discussed how earlier recognition and systemic therapy options are changing the treatment paradigm for patients with NF1-associated plexiform neurofibromas.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
ELEVIDYS Shows Functional Benefits in Patients With DMD, Dompé Launches Phase 2 Trial of Intranasal Nerve Growth Factor in CP, NeurologyLive Roundtable: The Road Ahead for Precision Medicine in MS
2
The Road Ahead for Precision Medicine in Multiple Sclerosis
3
Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial
4
RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial
5